Results 261 to 270 of about 3,868,024 (353)
Sources of Information and Pharmacists' Knowledge Regarding Rare Diseases and Orphan Drugs: Cross-Sectional Study In Serbia [PDF]
Jasmina Arsić+4 more
openalex +1 more source
Orphan drugs: Indian perspective
Harish Kumar, Bikash Medhi, Phulen Sarma
openaire +3 more sources
Pischiutta F and coworkers identify prostaglandins and kynurenine as key mediators of the mesenchymal stromal cells‐derived secretome's neuroprotective effects. A synthetic cocktail composed of these factors promotes long‐term functional recovery, reduces brain structural damage, and modulates neuroinflammation after traumatic brain injury, supporting ...
Francesca Pischiutta+24 more
wiley +1 more source
The Orphan Drug Act at 40: Legislative Triumph and the Challenges of Success. [PDF]
Saltonstall P, Ross H, Kim PT.
europepmc +1 more source
Objective This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by using high‐resolution peripheral quantitative computed tomography (HR‐pQCT). Methods This was a phase 4, double‐blind, randomized, placebo‐controlled trial.
Yingzhao Jin+11 more
wiley +1 more source
This study presents a real‐world analysis of patients with advanced solid tumors discussed at the Molecular Tumor Board (MTB) of University Hospital Brno, Czech Republic, between 2021 and 2025. Comprehensive genomic profiling guided matched therapies in 17.4% of cases, with a clinical benefit (PFS2/PFS1 ≥ 1.3) observed in 41.4% of evaluable patients ...
Michal Eid+19 more
wiley +1 more source
Access to orphan drugs in the Middle East: Challenge and perspective
Ziyad S. Almalki
openalex +2 more sources
Challenges in Measuring the Societal Value of Orphan Drugs: Insights from a Canadian Stated Preference Survey [PDF]
Nick Dragojlovic+5 more
openalex +1 more source
FDA Approval of Orphan Drug Indications for Pediatric Patients, 2011-2023.
Kakkilaya A, Shahzad M, Bourgeois FT.
europepmc +1 more source